Rulan Jiang1, Bo Lönnerdal2. 1. Department of Nutrition, University of California, Davis, CA, 95616, USA. 2. Department of Nutrition, University of California, Davis, CA, 95616, USA. bllonnerdal@ucdavis.edu.
Abstract
BACKGROUND: Osteopontin (OPN), a multifunctional protein, is present abundantly in human milk, but not in bovine milk and infant formulas. A recent randomized clinical trial showed that supplementing infant formula with bovine milk OPN (bOPN) resulted in better immune outcomes. METHODS: Human milk OPN (hOPN) concentrations were analyzed by ELISA. Plasma samples were obtained from infants receiving one of four treatments: breast milk (BF), unsupplemented formula (F0), formula supplemented with 65 mg/L bOPN (F65), or with 130 mg/L bOPN (F130). Plasma samples were analyzed for hOPN and bOPN by ELISA. RESULTS: The hOPN concentration was high in early lactation (D1 to D8), decreased gradually after D9, and deceased significantly after 1 month. At 4 and 6 months, higher levels of hOPN were found in plasma samples from the BF, F65, and F130 groups than in samples from the F0 group; the plasma bOPN concentration in the F130 group was greater than that in the F65 group. CONCLUSION: Dynamic changes in the concentration of milk OPN may reflect infant needs for different amounts of milk OPN for various functions at different developmental stages. Supplemental bOPN in infant formula may exert its beneficial effects by increasing endogenous OPN in plasma.
BACKGROUND: Osteopontin (OPN), a multifunctional protein, is present abundantly in human milk, but not in bovine milk and infant formulas. A recent randomized clinical trial showed that supplementing infant formula with bovine milk OPN (bOPN) resulted in better immune outcomes. METHODS: Human milk OPN (hOPN) concentrations were analyzed by ELISA. Plasma samples were obtained from infants receiving one of four treatments: breast milk (BF), unsupplemented formula (F0), formula supplemented with 65 mg/L bOPN (F65), or with 130 mg/L bOPN (F130). Plasma samples were analyzed for hOPN and bOPN by ELISA. RESULTS: The hOPN concentration was high in early lactation (D1 to D8), decreased gradually after D9, and deceased significantly after 1 month. At 4 and 6 months, higher levels of hOPN were found in plasma samples from the BF, F65, and F130 groups than in samples from the F0 group; the plasma bOPN concentration in the F130 group was greater than that in the F65 group. CONCLUSION: Dynamic changes in the concentration of milk OPN may reflect infant needs for different amounts of milk OPN for various functions at different developmental stages. Supplemental bOPN in infant formula may exert its beneficial effects by increasing endogenous OPN in plasma.
Authors: Y U Katagiri; J Sleeman; H Fujii; P Herrlich; H Hotta; K Tanaka; S Chikuma; H Yagita; K Okumura; M Murakami; I Saiki; A F Chambers; T Uede Journal: Cancer Res Date: 1999-01-01 Impact factor: 12.701
Authors: Dominique Turck; Jacqueline Castenmiller; Stefaan De Henauw; Karen Ildico Hirsch-Ernst; John Kearney; Alexandre Maciuk; Inge Mangelsdorf; Harry J McArdle; Androniki Naska; Carmen Pelaez; Kristina Pentieva; Alfonso Siani; Frank Thies; Sophia Tsabouri; Marco Vinceti; Francesco Cubadda; Thomas Frenzel; Marina Heinonen; Miguel Prieto Maradona; Rosangela Marchelli; Monika Neuhäuser-Berthold; Morten Poulsen; Josef Rudolf Schlatter; Henk van Loveren; Wolfgang Gelbmann; Helle Katrine Knutsen Journal: EFSA J Date: 2022-05-06
Authors: Brian Christensen; Andrea E Toth; Simone S E Nielsen; Carsten Scavenius; Steen V Petersen; Jan J Enghild; Jan T Rasmussen; Morten S Nielsen; Esben S Sørensen Journal: Nutrients Date: 2020-10-16 Impact factor: 5.717